Ann: New Clinical Practice Guidance Recommends Use of BIS, page-26

The question for me is whether or not this article supports the view that SOZO machine will enable IPD to establish a monopoly in the US for early monitoring of BCRAL (the raison d'etre for IPD at the moment).

In my view that is a definite no, there are too many unanswered questions that this article raises.

Which logically follows that instead of the anticipated exponential growth of a year ago, we are more likely to see a long slow grind to achieving sales, which makes a company losing $20m+ per year much less attractive and much more risky proposition in February 2024.